0001193125-12-415394.txt : 20121004 0001193125-12-415394.hdr.sgml : 20121004 20121004161545 ACCESSION NUMBER: 0001193125-12-415394 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120929 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20121004 DATE AS OF CHANGE: 20121004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 121129740 BUSINESS ADDRESS: STREET 1: 7 WELLS AVENUE STREET 2: STE 34 CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-559-0033 MAIL ADDRESS: STREET 1: 7 WELLS AVENUE STREET 2: STE 34 CITY: NEWTON STATE: MA ZIP: 02459 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 8-K 1 d420805d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

September 29, 2012

Date of Report (Date of earliest event reported)

 

 

GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

NEVADA   001-31791   04-3562325

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD

NORCROSS, GA 30071

(Address of principal executive offices) (Zip Code)

(617) 559-0033

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.02 Termination of a Material Definitive Agreement.

Effective September 29, 2012, Galectin Therapeutics Inc. (the “Company”) terminated its Collaboration, Supply, Marketing and Distribution Agreement, dated October 18, 2011 (the “Agreement”), with PROCAPS, S.A (“PROCAPS”) due to a material breach, as PROCAPS had not obtained regulatory approval of GM-CT-01 in Colombia by the required date in accordance with the terms of the Agreement. A description of the material terms of the Agreement are contained in the Form 8-K filed by the Company on October 24, 2011, and the Agreement is filed as Exhibit 10.2 to the Company’s Form 10-Q for the quarter ended September 30, 2011, both of which are incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

GALECTIN THERAPEUTICS INC.
By:  

/s/ Peter G. Traber

  Peter G. Traber, M.D.
  President, Chief Executive Officer & Chief Medical Officer

Date: October 4, 2012